AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35632416
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of live attenuated varicella vaccine (VarV) administered 1 year after primary immunization (Group 1)
Trial: 35632416
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of live attenuated varicella vaccine (VarV) administered 2 years after primary immunization (Group 2)
Trial: 35632416
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of live attenuated varicella vaccine (VarV) administered 3 years after primary immunization (Group 3)
Trial: 35633970
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of autologous thymic-derived regulatory T cells (thyTreg)
Trial: 35634171
Drug: Photothermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photothermal therapy
Trial: 35634417
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of a dietary multi-ingredient nootropic
Trial: 35634506
Drug: Irisin serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irisin serum levels in CMT patients (6.51 ± 2.26 μg/ml)
Trial: 35634506
Drug: Irisin serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irisin serum levels in CMT patients with pathological muscle strength (5.56 ± 1.26 μg/ml)
Trial: 35634506
Drug: Irisin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irisin levels in women (7.31 ± 2.53 μg/ml)
Trial: 35635640
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg daily until disease progression or unacceptable toxicity
Trial: 35635644
Drug: Iodine-containing supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-containing supplements (ICS)
Trial: 35635644
Drug: No iodine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iodine-containing supplements (non-users)
Trial: 35635728
Drug: Tiotropium /
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium / olodaterol combination treatment
Trial: 35635746
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy and smartphone-based National Cancer Institute QuitGuide app
Trial: 35636792
Drug: Volume of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume of first 24-hours blood product administration
Trial: 35636921
Drug: Erlotinib 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 350 mg once weekly for 6 months
Trial: 35637081
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PNI and serum sodium level
Trial: 35639457
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g daily collagen peptide supplement
Trial: 35639644
Drug: mRNA (BNT162b2)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA (BNT162b2) vaccine
Trial: 35639825
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 1 (n = 8)
Trial: 35639825
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 2 (n = 4)
Trial: 35639825
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 3 (n = 9)
Trial: 35639922
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) treatment in CARDS patients
Trial: 35640276
Drug: UGN-102 (mitomycin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 (mitomycin-containing reverse thermal gel), 6 weekly instillations
Trial: 35640276
Drug: UGN-102 (mitomycin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 (mitomycin-containing reverse thermal gel)
Trial: 35640474
Drug: NLG207 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLG207 12 mg/m2 in combination with enzalutamide
Trial: 35640864
Drug: Community-based pelvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based pelvic floor physical therapy
Trial: 35640864
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BET with squeeze duration (BET > 6.5 seconds and limited squeeze duration)
Trial: 35641194
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of phylloquinone thrice weekly
Trial: 35641481
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg (day 1), Apatinib 250 mg daily, Eribulin 1.4 mg/m²
Trial: 35641780
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg) with milvexian (30 mg)
Trial: 35641780
Drug: Diltiazem (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (240 mg) with milvexian (30 mg)
Trial: 35642431
Drug: ABBV-011 (calicheamicin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-011 (calicheamicin-based antibody-drug conjugate)
Trial: 35643089
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (300 mg orally once a day from the 24th week of gestation until 6 weeks postpartum)
Trial: 35643571
Drug: Concentric LV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentric LV remodeling in T2D (mass/volume 0.91±0.15 g/mL)
Trial: 35643589
Drug: BEMPEG 0.006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEMPEG 0.006 mg/kg plus nivolumab 360 mg intravenously every 3 weeks
Trial: 35643624
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 125 mg/d
Trial: 35643624
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 75/100 mg/d
Trial: 35643624
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus an aromatase inhibitor (PAL+AI)
Trial: 35646641
Drug: High-dose methotrexate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate-based treatment
Trial: 35647062
Drug: Sequential Multi-Point
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Multi-Point Pacing
Trial: 35647711
Drug: Danuglipron (PF-06882961),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron (PF-06882961), an orally bioavailable small-molecule GLP-1R agonist, administered orally.
Trial: 35647908
Drug: sintilimab 200
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab 200 mg every 3 weeks (21 patients), 1 mg/kg every 2 weeks (2 patients), 3 mg/kg every 2 weeks (1 patient)
Trial: 35647938
Drug: G/nab-P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/nab-P
Trial: 36701676
Drug: Allergen Immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen Immunotherapy
Trial: 35650616
Drug: Higher cumulative
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cumulative fluid balance (median 1.98 L)
Trial: 35650616
Drug: Intermediate cumulative
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate cumulative fluid balance (median 0.78 L)
Trial: 35650616
Drug: Lower cumulative
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower cumulative fluid balance (median -0.35 L)
Trial: 35650617
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity on prescription (PAP) intervention
Trial: 35651792
Drug: BCMA CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA CAR-T cell therapy
Trial: 35651792
Drug: Previous treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatments (bortezomib, Adriamycin, dexamethasone, lenalidomide, daratumumab)
Trial: 35651818
Drug: Different sequenced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different sequenced pharmacotherapy options
Trial: 35651818
Drug: SSRIs (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (first-line pharmacotherapy)
Trial: 35652112
Drug: Methylprednisolone 40
RxNorm normalized name: methylprednisolone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 40 mg during the first CPR cycle and hydrocortisone 240 mg daily for 7 days maximum (steroids group)
Trial: 35652820
Drug: Nonfermented dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonfermented dairy intake (each 100-g increase)
Trial: 35653029
Drug: OC-01 VNS
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 VNS (0.06 mg)
Trial: 36280870
Drug: SHR-1701 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1701 at 30 mg/kg every 3 weeks
Trial: 35653138
Drug: HPV vaccination
RxNorm normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccination as an adjuvant treatment
Trial: 35653552
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg monovalent HepB vaccine
Trial: 35654732
Drug: Epitinib 120
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Epitinib 120 mg QD
Trial: 35654732
Drug: Epitinib 160
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Epitinib 160 mg QD
Trial: 35655320
Drug: FGF401 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF401 (120 mg qd)
Trial: 35655320
Drug: FGF401 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF401 plus spartalizumab (FGF401 120 mg qd and spartalizumab 300 mg Q3W)
Trial: 35655320
Drug: FGF401 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF401 (50 to 150 mg)
Trial: 35656720
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT: 1 anticoagulant and 2 antiplatelet agents)
Trial: 35656720
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (1 anticoagulant + 1 antiplatelet agent)
Trial: 35656931
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants for treating AF
Trial: 35657428
Drug: Gallium-68-labeled fibroblast
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallium-68-labeled fibroblast activation protein inhibitor PET
Trial: 35657653
Drug: PF-06747775 monotherapy
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06747775 monotherapy at recommended Phase 2 dose (200 mg QD)
Trial: 35657653
Drug: PF-06747775 200
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-06747775 200 mg QD plus palbociclib (100 mg QD orally)
Trial: 35657653
Drug: PF-06747775 monotherapy
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06747775 monotherapy at RP2D in a Japanese lead-in cohort
Trial: 35657979
Drug: Pembrolizumab+chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab+chemotherapy
Trial: 37099736
Drug: Adagrasib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adagrasib (600 mg orally twice daily)
Trial: 35658469
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion after lymphodepletion
Trial: 35659282
Drug: Intravenous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab (TCZ) 7 mg/kg Q4W
Trial: 35659282
Drug: Intravenous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab (TCZ) 6 mg/kg Q4W
Trial: 35659282
Drug: Intravenous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab (TCZ) 8 mg/kg Q4W (previous treatment)
Trial: 35659581
Drug: Limertinib 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limertinib 160 mg orally twice daily
Trial: 35660797
Drug: Dostarlimab (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (anti-PD-1 monoclonal antibody), administered every 3 weeks for 6 months
Trial: 35663154
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ) therapy
Trial: 35663767
Drug: 7.5% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% urea cream
Trial: 35663767
Drug: Basic moisturizer
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic moisturizer (vehicle cream)
Trial: 35664443
Drug: Single-dose Vi-DT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose Vi-DT (n=252)
Trial: 35665739
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of autologous total IgG (50 mg, 8 injections over 4 weeks)
Trial: 35667016
Drug: Befovacimab 100
RxNorm normalized name: Befovacimab
DrugBank: Befovacimab (DB16188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befovacimab 100 mg
Trial: 35667016
Drug: Befovacimab 225
RxNorm normalized name: Befovacimab
DrugBank: Befovacimab (DB16188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befovacimab 225 mg
Trial: 35667016
Drug: Befovacimab 400
RxNorm normalized name: Befovacimab
DrugBank: Befovacimab (DB16188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befovacimab 400 mg
Trial: 35667016
Drug: Befovacimab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befovacimab (all doses)
Trial: 35667271
Drug: Nutritional Quality
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional Quality Improvement Program (QIP) including education, dietary counseling, and oral nutritional supplements (ONS) for daily intake over 60 days.
Trial: 35667399
Drug: Telehealth physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth physical therapy (PT)
Trial: 35667558
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine or mRNA-1273 vaccine, administered in two or three doses
Trial: 35667724
Drug: Remote self-administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote self-administered speech tasks
Trial: 35669398
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (10 mg/kg/day for 3 days)
Trial: 35669398
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIG) (2 g/kg as a single dose)
Trial: 35671038
Drug: Tralokinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab (300 mg) administered subcutaneously every 4 weeks
Trial: 35671108
Drug: Guadecitabine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab (200 mg i.v.) on day 5, every 21 days
Trial: 35671201
Drug: Tremelimumab 3
RxNorm normalized name: TREMELIMUMAB 300 mg in 15 mL INTRAVENOUS INJECTION, SOLUTION [IMJUDO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 3 or 10 mg/kg (Q4W for 6 doses/Q12W thereafter until discontinuation)
Trial: 35671201
Drug: Tremelimumab 10
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 10 mg/kg (Q4W for 6 doses/Q12W for 3 doses) plus durvalumab 15 mg/kg (Q4W for 13 doses)
Trial: 35671201
Drug: Tremelimumab 1
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 1 mg/kg (Q4W for 4 doses) plus durvalumab 20 mg/kg (Q4W for 4 doses followed by 10 mg/kg Q2W for 22 doses)
Trial: 35671201
Drug: Fixed-dose tremelimumab
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses)
Trial: 35671201
Drug: Tremelimumab 10
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 10 mg/kg (Q4W/Q12W)
Trial: 35672037
Drug: Patient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient treatment choices
Trial: 35672688
Drug: NEIVATECH virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEIVATECH virtual reality system (group A) - 18 half-hour in-office therapy sessions for 3 months
Trial: 35672754
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment after Monteggia injury
Trial: 35672923
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (dosage and duration not available)
Trial: 35674480
Drug: Lenvatinib (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (dosage not specified, administered daily)
Trial: 35674880
Drug: Tirzepatide (5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (5-mg subcutaneous dose)
Trial: 35675370
Drug: BNT162b2 (mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (mRNA vaccine)
Trial: 35675590
Drug: Ponatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT)
Trial: 35675590
Drug: Ponatinib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib with chemotherapy followed by alloHSCT
Trial: 35676017
Drug: Multivariate model
RxNorm normalized name: polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivariate model derived from high dimensional data set including epidemiological, psychometric, quantitative sensory, brain imaging and biological information
Trial: 35676062
Drug: Cetuximab and
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab and nivolumab combination therapy
Trial: 35677040
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment during pregnancy
Trial: 35677040
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral treatment during pregnancy
Trial: 35677980
Drug: Vaccine-induced immune
RxNorm normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-induced immune thrombotic thrombocytopenia (VITT) cases in the first 5 months of 2021